Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea
If successful, this pharmacologic approach could substantially change the treatment paradigm for OSA patients. “There is a clear unmet need for an approach that addresses the underlying cause
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.